Articles from ATED Therapeutics Ltd.

ATED Therapeutics Ltd. has been named the winner of the Fierce Life Sciences Innovation Award in the Medical Device Category, recognizing its rapid blood test for Parkinson’s Disease. The award honors ATED’s pioneering use of transfer RNA fragments (tRFs) and quantitative PCR (qPCR) to deliver fast, accurate, and scalable diagnostics for one of the world’s fastest-growing neurodegenerative conditions.

ATED Therapeutics Ltd. announced a new diagnostic test for Parkinson’s Disease, developed at Hebrew University in Jerusalem, Israel. The test measures transfer RNA fragments (tRF’s) from nucleated red blood cells. Results were published in the April 2025 issue of Nature Aging and recently presented at the International Conference on Alzheimer’s, Parkinson’s and Related Neurologic Diseases in Vienna, Austria on April 2.

The winners and finalists of Fast Company’s 2024 World Changing Ideas Awards were announced today, highlighting fresh sustainability initiatives, cutting-edge AI developments, ambitious pursuits of social equity, and other creative projects that are helping mold the world.